Immunovant, Inc.
IMVT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001764013
In the last 90 days, Immunovant, Inc. insiders filed 0 open-market purchases and 10 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.25B in total; Greenlight Capital is the only superinvestor holding it.
Holders of 5% or more of IMVT
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Immunovant, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Roivant Sciences Ltd. | 13D/A | 55.90%113.3M shares | −1.00 ppfrom 56.90% | Mar 8, 20216 filings | Dec 12, 2025 | SEC |
| FMR LLC | 13G/A | 8.40%14.7M shares | −1.70 ppfrom 10.10% | Feb 9, 20244 filings | Nov 5, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
18 Schedule 13D and 13G filings on Immunovant, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 20268:27 AM ET | Deep Track Capital, LPand 2 others | 13G/A | 4.55%9.34M shares | −1.04 ppfrom 5.59%Below 5% | Jun 30, 2026 | SEC |
| Dec 12, 20255:20 PM ET | Roivant Sciences Ltd. | 13D/A | 55.90%113.3M shares | −1.00 ppfrom 56.90% | Dec 12, 2025 | SEC |
| Nov 5, 202511:35 AM ET | FMR LLCand 1 other | 13G/A | 8.40%14.7M shares | −1.70 ppfrom 10.10% | Sep 30, 2025 | SEC |
| Apr 21, 20257:54 AM ET | Roivant Sciences Ltd. | 13D/A | 56.90%96.7M shares | 0.00 ppfrom 56.90% | Apr 21, 2025 | SEC |
| Mar 26, 20254:09 PM ET | Deep Track Capital, LPand 2 others | 13G | 5.59%9.50M shares | – | Mar 19, 2025 | SEC |
| Mar 7, 202510:01 AM ET | FMR LLCand 1 other | 13G/A | 10.10%17.1M shares | – | Feb 28, 2025 | SEC |
| Jan 15, 20254:30 PM ET | Roivant Sciences Ltd. | 13D/A | 56.90%96.7M shares | – | Jan 13, 2025 | SEC |
| Nov 12, 2024 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2024 | Deep Track Capital, LP | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2024 | FMR LLC | 13GOld format | – | New | – | SEC |
| Oct 4, 2023 | Roivant Sciences Ltd. | 13D/AOld format | – | – | – | SEC |
| Feb 14, 2023 | Deep Track Capital, LP | 13G/AOld format | – | – | – | SEC |
| Dec 5, 2022 | RTW Investments, LP | 13G/AOld format | – | – | – | SEC |
| Dec 2, 2022 | RTW Investments, LP | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2022 | Deep Track Capital, LP | 13GOld format | – | New | – | SEC |
| Aug 2, 2021 | Roivant Sciences Ltd. | 13D/AOld format | – | – | – | SEC |
| Mar 8, 2021 | Roivant Sciences Ltd. | 13D/AOld format | – | – | – | SEC |
| Feb 16, 2021 | RTW Investments, LP | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Immunovant, Inc. shares.
No Form 144 notices for Immunovant, Inc. are on file.